TABLE 1.
Demographics and baseline characteristics of participants in the single‐rising dose study
| Placebo fasted + fed (n = 20) | BI 705564 | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fasted | Fed | Food effect | ||||||||||
| 1 mg (n = 6) | 3 mg (n = 5) | 10 mg (n = 6) | 20 mg (n = 6) | 40 mg (n = 6) | 80 mg (n = 6) | 20 mg (n = 6) | 40 mg (n = 6) | 80 mg (n = 6) | 160 mg (n = 6) | 10 mg a (n = 12) | ||
| Age (y), median (range) | 39 (19–48) | 35 (31–43) | 29 (20–43) | 34 (22–46) | 32 (24–48) | 37 (26–49) | 35 (26–50) | 36 (29–49) | 30 (21–39) | 33 (25–48) | 39 (29–48) | 30 (19–50) |
| Height (cm), mean (SD) | 180 (5) | 180 (7) | 177 (4) | 180 (5) | 181 (8) | 175 (9) | 176 (5) | 180 (6) | 179 (9) | 184 (6) | 176 (5) | 178 (5) |
| BMI (kg/m2), mean (SD) | 25 (2) | 24 (3) | 23 (2) | 24 (3) | 24 (3) | 25 (3) | 25 (2) | 26 (3) | 23 (2) | 25 (3) | 27 (2) | 24 (3) |
a
Two participants in the 10 mg BI 705564 food effect group were also included in other groups (1 in the placebo group and 1 in the 3 mg BI 705564 group).
BMI, body mass index; SD, standard deviation.